| Cat.No. | Name | Information |
|---|---|---|
| M43286 | SRC-1 NR box peptide | SRC-1 NR box peptide is a biological active peptide. |
| M43285 | IRS1-derived peptide | IRS1-derived peptide is a biological active peptide. |
| M43284 | Ala-Ala-Ala-Ala | Ala-Ala-Ala-Ala is a poly-L-alanine (PLA) sequences. |
| M43283 | Cdc2 kinase substrate | Cdc2 kinase substrate is a biological active peptide. |
| M43282 | 5-FAM-PMDM6 | 5-FAM-PMDM6 (PMDM6-F) is a biological active peptide. |
| M43281 | Goserelin EP Impurity E | Goserelin EP Impurity E is the impurity of Goserelin. |
| M43280 | Dabcyl-QALPETGEE-Edans | Dabcyl-QALPETGEE-Edans is a biological active peptide. |
| M43279 | MeO-Suc-Arg-Pro-Tyr-pNA | MeOSuc-Arg-Pro-Tyr-pNA is a biological active peptide. |
| M43278 | BDC2.5 Mimotope 1040-63 | BDC2.5 Mimotope 1040-63 is a biological active peptide. |
| M43277 | p70 S6 Kinase substrate | p70 S6 Kinase substrate is a biological active peptide. |
| M43276 | Dabcyl-AGHDAHASET-Edans | Dabcyl-AGHDAHASET-Edans is a biological active peptide. |
| M43275 | C5aR1 antagonist peptide | C5aR1 antagonist peptide is a biological active peptide. |
| M43274 | ERK2 Substrate | ERK2 Substrate (Erktide) is a biological active peptide. |
| M43273 | LCMV-derived p13 epitope | LCMV-derived p13 epitope is a biological active peptide. |
| M43272 | RS Domain derived peptide | RS Domain derived peptide is a biological active peptide. |
| M43271 | beta-Casein phosphopeptide | beta-Casein phosphopeptide is a biological active peptide. |
| M43270 | VPSTPPTPSPSTPPTPSPS TFA | VPSTPPTPSPSTPPTPSPS (TFA) is an IgA1 hinge region peptide. |
| M43269 | TPNQRQNVC | TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. |
| M43268 | VHLTP | VHLTP is the N-terminal pentapeptide of human hemoglobin beta. |
| M43267 | CCK1-specific peptide substrate | CCK1-specific peptide substrate is a biological active peptide. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
